|
Treatment for Neuropsychiatric Disorders by Intravitreal Injection of DREADD Followed by Eye Drops or Pills Containing DREADD agonist
Figure 1. DREADD receptor-mediated activation of retinal cells prevents the development of light deprivation-induced depression-like behavior in vivo. A. DD-hM3Dq activation prevents the relative weight loss that was induced by constant dark lighting conditions. B. DREADD receptor-mediated activation of retinal cells leads to a reduction of depression-like...
Published: 10/26/2022
|
Inventor(s): Gary Aston-Jones, Hannah Bowrey
Keywords(s): Gene editing, Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
